½ÃÀ庸°í¼­
»óǰÄÚµå
1812452

¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå : Á¦Çüº°, À¯Çüº°, Åõ¿© °æ·Îº°, ¿ë·®º°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°

Naproxen Market, By Dosage Form, By Type, By Route of Administration, By Dosage Strength, By Application, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀåÀº 2025³â 3¾ï 2,040¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2023³â±îÁö 5¾ï 3,570¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ¸·Î, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR) 7.65%·Î ¼ºÀåÀÌ ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 3¾ï 2,040¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2020-2024³â
¿¹Ãø±â°£ : 2025-2032³â CAGR : 7.65% 2032³â °¡Ä¡ ¿¹Ãø 5¾ï 3,570¸¸ ´Þ·¯

¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀåÀº Á¦¾à ¾÷°è¿¡¼­ Áß¿äÇÑ ºÎ¹®ÀÌ¸ç ¼¼°è¿¡¼­ °¡Àå ³Î¸® ó¹æµÇ´Â ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs) Áß ÇϳªÀÔ´Ï´Ù. ÇÁ·ÎÇǿ»ê À¯µµÃ¼ÀÎ ³ªÇÁ·Ï¼¾Àº °üÀý¿°, ¿ù°æÅë, µÎÅë, ´Ù¾çÇÑ ±Ù°ñ°Ý°è Áúȯ µî ´Ù¾çÇÑ º´¸®¿¡¼­ ÅëÁõ, ¿°Áõ, ¹ß¿­À» °ü¸®Çϱâ À§ÇÑ ±âº» Ä¡·áÁ¦ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±× È¿´ÉÀº ½ÃŬ·Î¿Á½Ã°Ô³ª¾ÆÁ¦ È¿¼Ò, ƯÈ÷ COX-2¸¦ ¼±ÅÃÀûÀ¸·Î ÀúÇØÇÏ´Â °Í¿¡ ±âÀÎÇϸç, ¿°Áõ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ÇÁ·Î½ºÅ¸±Û¶õµò ÇÕ¼ºÀ» °¨¼Ò½Ãŵ´Ï´Ù.

ÀÌ ½ÃÀåÀº Áï½Ã ¹æÃâ Á¤Á¦, ¼­¹æÇü Á¦Á¦, °æ±¸ Çöʾ×, ±¹¼Ò¿ë Á¦Á¦ µî ´Ù¾çÇÑ Á¦Á¦¸¦ Æ÷ÇÔÇÏ¿© ´Ù¾çÇÑ È¯ÀÚÃþ°ú Ä¡·á Çʿ信 ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. 󹿾àÀ¸·Î¼­µµ ½ÃÆÇ¾àÀ¸·Î¼­µµ ÀÔ¼ö °¡´ÉÇÑ ³ªÇÁ·Ï¼¾Àº ±× ÀÔ¼öÀÇ ¿ëÀ̼ºÀÌ ¼¼°èÀûÀÎ ½ÃÀå ħÅõ¿¡ Å©°Ô °øÇåÇϰí ÀÖ½À´Ï´Ù. ³ªÇÁ·Ï¼¾À» µÑ·¯½Ñ Á¦¾à Á¤¼¼¿¡´Â Á¦³×¸¯ Á¦Á¶¾÷ü, ºê·£µå Á¦Á¦, º´¿ë ¿ä¹ý µîÀÌ ÀÖ¾î ±â¼ú Çõ½Å°ú ºñ¿ë È¿°ú¸¦ ÃËÁøÇÏ´Â °æÀï »ýŰ谡 Çü¼ºµÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

³ªÇÁ·Ï¼¾ ¼¼°è ½ÃÀåÀº ¸¸¼º ¿°Áõ¼º Áúȯ, ƯÈ÷ °üÀý¿°°ú ·ù¸¶Æ¼½º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÁÖ¿ä ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù. ³ëÀÎÃþ¿¡¼­´Â NSAID Ä¡·á°¡ ÇÊ¿äÇÑ ±Ù°ñ°Ý°è Àå¾Ö, ¸¸¼º ÅëÁõ, ¿°Áõ¼º ÁúȯÀÇ ÀÌȯÀ²ÀÌ ³ô±â ¶§¹®¿¡ ¼¼°è Àα¸ÀÇ °í·ÉÈ­°¡ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÅëÁõ°ü¸®¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·á Á¢±ÙÀÇ °³¼±°ú ÇÔ²² ³ªÇÁ·Ï¼¾À» ±â¹ÝÀ¸·Î ÇÏ´Â Ä¡·áÁ¦ ¼ö¿ä°¡ ´õ¿í ´Ã¾î³ª°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ´Ù¸¥ ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦¿¡ ºñÇØ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀÌ ¾çÈ£ÇÑ °Í, º¹¼öÀÇ Á¦Á¦¸¦ ÀÔ¼öÇÒ ¼ö ÀÖ´Â °Í, Á¦³×¸¯ ÀǾàǰ ¶§¹®¿¡ ºñ¿ë ´ëºñ È¿°ú°¡ ³ôÀº µîµµ ½ÃÀå µµÀÔÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

±×·¯³ª NSAIDÀÇ Àå±â »ç¿ë¿¡ ¼ö¹ÝÇÏ´Â ½ÉÇ÷°ü°è¿Í ¼ÒÈ­±â°èÀÇ ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁö°í, ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã³ª ó¹æ °¡À̵å¶óÀÎÀÇ ¾ö°ÝÈ­°¡ ÁøÇàµÇ´Â µî, ½ÃÀåÀº Å« ¾ïÁ¦¿äÀο¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î »ý¹°ÇÐÀû Á¦Çü, ±¹¼Ò ÁøÅëÁ¦, ºñ¾à¹° ¿ä¹ý°ú °°Àº ´ëü ÅëÁõ °ü¸® ¿ä¹ý°úÀÇ °æÀïÀº ½ÃÀå È®´ëÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ºê·£µå Á¦Á¦ÀÇ Æ¯Çã ¸¸·áÀº Á¦³×¸¯ ÀǾàǰ°úÀÇ °æÀïÀ» °ÝÈ­½ÃÄÑ Á¦¾à ȸ»çÀÇ ÀÌÀÍ·üÀ» ¾Ð¹ÚÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ Æ¯Á¤ Áö¿ª¿¡¼­´Â ½ÃÆÇ¾à¿¡ ´ëÇÑ ±ÔÁ¦°¡ ÀÖÀ¸¸ç õ¿¬ À¯·¡ Ç׿°ÁõÁ¦¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í Á¦¾àÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, Ä¡·á È¿°ú¸¦ À¯ÁöÇϸ鼭 ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛ, ¼­¹æÇü Á¦Çü ¹× º´¿ë ¿ä¹ýÀÇ °³¹ß¿¡´Â Å« ºñÁî´Ï½º ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ½ÅÈï ½ÃÀåÀº ÀÇ·á ÀÎÇÁ¶ó °³¼±, ÀÇ·áºñ Áõ°¡, Áúº´ ºÎ´ã Áõ°¡·Î Å« ¼ºÀå ÀáÀç·ÂÀ» Áö´Ï°í ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ßÀ» À§ÇÑ Á¦¾à±â¾÷ °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¿¡ ´ëÇÑ Áַ°ú ÇÔ²² ³ªÇÁ·Ï¼¾ Ä¡·áÀÇ Àü¸Á¿¡¼­ ½ÃÀå È®´ë¿Í Çõ½ÅÀÇ ±æÀ» °³Ã´ÇÕ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(USD Mn)¿Í ¿¬°£ º¹ÇÕ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È Çà·Ä¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ³ªÇÁ·Ï¼¾ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ³ªÇÁ·Ï¼¾ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀåÀ» ºÐ¼®Çϴµ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À
  • ¾÷°è µ¿Çâ

Á¦4Àå ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå, Á¦Çüº°, 2020-2032³â

  • Á¤Á¦ ¹× ĸ½¶
  • Çöʾ×
  • Á©

Á¦5Àå ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå, À¯Çüº°, 2020-2032³â

  • ºê·£µå
  • Á¦³×¸¯

Á¦6Àå ³ªÇÁ·Ï¼¾ ¼¼°è ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â

  • °æ±¸
  • ºñ°æ±¸
  • ±¹ºÎ

Á¦7Àå ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå, ¿ë·®º°, 2020-2032³â

  • ³·À½(250mg ÀÌÇÏ)
  • Áß(251-500mg)
  • °í(500mg Ãʰú)

Á¦8Àå ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå, ¿ëµµº°, 2020-2032³â

  • °ñ°üÀý¿°
  • ·ù¸¶Æ¼½º °üÀý
  • °­Á÷¼º ôÃß¿°
  • ¿¬¼Ò¼º °üÀý¿°
  • Ȱ¾×³²¿°
  • ¿ø¹ß¼º ¿ù°æ°ï¶õÁõ
  • ±Þ¼º Åëdz
  • °Ç¿°
  • ÅëÁõ ¿ÏÈ­(°æµµ-Áߵ)

Á¦9Àå ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦10Àå ¼¼°èÀÇ ³ªÇÁ·Ï¼¾ ½ÃÀå, Áö¿ªº°, 2020-2032³â, °¡Ä¡

  • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ½ºÆäÀÎ
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ·¯½Ã¾Æ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • Àεµ
      • ÀϺ»
      • È£ÁÖ
      • Çѱ¹
      • ASEAN
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
      • GCC ±¹°¡
      • À̽º¶ó¿¤
      • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
      • ³²¾ÆÇÁ¸®Ä«
      • ºÏ¾ÆÇÁ¸®Ä«
      • Áß¾Ó ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï ±¸µµ

  • Teva Pharmaceutical Industries Ltd.
  • Reddy's Laboratories Ltd.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Divis Laboratories Ltd.
  • Zhejiang Charioteer Pharmaceutical Co., Ltd.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Huazhong Pharmaceutical Co., Ltd.
  • Guangzhou Tosun Pharmaceutical Co., Ltd.
  • Hainan Poly Pharm Co., Ltd.
  • Hy-Gro Chemicals, Inc.
  • Nishchem International Pvt. Ltd.
  • Solara Active Pharma Sciences Ltd.
  • Rochem International Inc.

Á¦12Àå ºÐ¼®°¡ Ãßõ

  • ±âȸ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map

Á¦13Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
JHS 25.09.26

Naproxen Market is estimated to be valued at USD 320.4 Mn in 2025 and is expected to reach USD 535.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.65% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 320.4 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.65% 2032 Value Projection: USD 535.7 Mn

The global Naproxen market represents a critical segment within the pharmaceutical industry, encompassing one of the most widely prescribed Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) worldwide. Naproxen, a propionic acid derivative, serves as a cornerstone therapeutic agent for managing pain, inflammation, and fever across diverse medical conditions including arthritis, menstrual cramps, headaches, and various musculoskeletal disorders. Its efficacy stems from the selective inhibition of cyclooxygenase enzymes, particularly COX-2, which reduces prostaglandin synthesis responsible for inflammatory responses.

The market encompasses various formulations including immediate-release tablets, extended-release formulations, oral suspensions, and topical preparations, catering to different patient demographics and therapeutic requirements. Available both as prescription medications and over-the-counter preparations, naproxen's accessibility has significantly contributed to its market penetration globally. The pharmaceutical landscape surrounding naproxen includes generic manufacturers, branded formulations, and combination therapies, creating a competitive ecosystem that drives innovation and cost-effectiveness.

Market Dynamics

The global Naproxen market is primarily driven by the increasing prevalence of chronic inflammatory conditions, particularly arthritis and rheumatoid disorders, which affect millions worldwide and require long-term anti-inflammatory management. The aging global population significantly contributes to market growth, as elderly demographics experience higher incidences of musculoskeletal disorders, chronic pain conditions, and inflammatory diseases that necessitate NSAID therapy. Rising awareness about pain management, coupled with improved healthcare accessibility in emerging markets, further propels demand for Naproxen-based treatments. Additionally, the drug's favorable safety profile compared to other NSAIDs, its availability in multiple formulations, and cost-effectiveness due to generic versions enhance the market adoption.

However, the market faces substantial restraints including increasing concerns about cardiovascular and gastrointestinal side effects associated with long-term NSAID use, which has led to stricter regulatory scrutiny and prescription guidelines. Competition from alternative pain management therapies, including newer biologics, topical analgesics, and non-pharmacological treatments, poses challenges to market expansion. Patent expirations of branded formulations have intensified generic competition, pressuring profit margins for pharmaceutical companies.

Regulatory restrictions on over-the-counter availability in certain regions and growing preference for natural anti-inflammatory alternatives further constrain the market growth. Nevertheless, significant opportunities exist in developing novel drug delivery systems, extended-release formulations, and combination therapies that minimize side effects while maintaining therapeutic efficacy. Emerging markets present substantial growth potential due to improving healthcare infrastructure, increasing healthcare expenditure, and rising disease burden. Strategic partnerships between pharmaceutical companies for research and development, along with focus on personalized medicine approaches, create avenues for the market expansion and innovation in the naproxen therapeutic landscape.

Key Features of the Study

  • This report provides in-depth analysis of the global Naproxen market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Naproxen market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Bayer AG, Divis Laboratories Ltd., Zhejiang Charioteer Pharmaceutical Co., Ltd., Jiangsu Nhwa Pharmaceutical Co., Ltd., Huazhong Pharmaceutical Co., Ltd., Guangzhou Tosun Pharmaceutical Co., Ltd., Hainan Poly Pharm Co., Ltd., Hy-Gro Chemicals, Inc., Nishchem International Pvt. Ltd., Solara Active Pharma Sciences Ltd., and Rochem International Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Naproxen market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Naproxen market.

Market Segmentation

  • Dosage Form Insights (Revenue, USD Mn, 2020 - 2032)
    • Tablets/Capsules
    • Suspension Liquid
    • Gels
  • Type Insights (Revenue, USD Mn, 2020 - 2032)
    • Brand
    • Generic
  • Route of Administration: Insights (Revenue, USD Mn, 2020 - 2032)
    • Oral
    • Parenteral
    • Topical
  • Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
    • Low (<=250 mg)
    • Medium (251-500 mg)
    • High (>500 mg)
  • Application Insights (Revenue, USD Mn, 2020 - 2032)
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Juvenile Arthritis
    • Bursitis
    • Primary Dysmenorrhea
    • Acute Gout
    • Tendonitis
    • Pain Relief (Mild to Moderate)
  • Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Mn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Teva Pharmaceutical Industries Ltd.
    • Reddy's Laboratories Ltd.
    • Aurobindo Pharma Ltd.
    • Bayer AG
    • Divis Laboratories Ltd.
    • Zhejiang Charioteer Pharmaceutical Co., Ltd.
    • Jiangsu Nhwa Pharmaceutical Co., Ltd.
    • Huazhong Pharmaceutical Co., Ltd.
    • Guangzhou Tosun Pharmaceutical Co., Ltd.
    • Hainan Poly Pharm Co., Ltd.
    • Hy-Gro Chemicals, Inc.
    • Nishchem International Pvt. Ltd.
    • Solara Active Pharma Sciences Ltd.
    • Rochem International Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Naproxen Market, By Dosage Form
    • Global Naproxen Market, By Type
    • Global Naproxen Market, By Route of Administration
    • Global Naproxen Market, By Dosage Strength
    • Global Naproxen Market, By Application
    • Global Naproxen Market, By Distribution Channel
    • Global Naproxen Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
    • Restraint
    • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Naproxen Market, By Dosage Form, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Tablets/Capsules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Suspension Liquid
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Gels
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Naproxen Market, By Type, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Brand
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Generic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Naproxen Market, By Route of Administration, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Naproxen Market, By Dosage Strength, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Low (<=250 mg)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Medium (251-500 mg)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • High (>500 mg)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Naproxen Market, By Application, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Osteoarthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Rheumatoid Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Ankylosing Spondylitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Juvenile Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Bursitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Primary Dysmenorrhea
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Acute Gout
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Tendonitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Pain Relief (Mild to Moderate)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Naproxen Market, By Distribution Channel, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Naproxen Market, By Region, 2020 - 2032, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration: 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Reddy's Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aurobindo Pharma Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Divis Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zhejiang Charioteer Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Huazhong Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Guangzhou Tosun Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hainan Poly Pharm Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hy-Gro Chemicals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Nishchem International Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Solara Active Pharma Sciences Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Rochem International Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About Us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦